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Introduction
Malignant tumors are generally characterized by somatic 
mutations. It is assumed that mutations develop over time 
and that the pattern may well be different in early and 
late stages. However, a new hypothesis suggests that most 
mutations occur in the early phase and that occurrence 
of late mutations is not likely to result in the develop-
ment of new clones [1]. Irrespective of the time course 
of development, somatic mutations represent important 
biological characteristics likely to influence the behavior 
of the tumor.
RAS/RAF mutations are early events in the development 
of colorectal cancer. The RAS/RAF proteins affect gene 
expression by encoding GTP- binding proteins, which act 
as molecular switches connecting extracellular signals with 
nuclear transcription factors. Mutations in RAS/RAF result 
in a constitutive activation of the Ras/Raf/Mek/Erk/Map 
pathway independent of the stimulation of the epidermal 
growth factor receptor (EGFR). This cascade facilitates 
growth and proliferation leading to migration and inva-
sion [2].
RAS mutations are point mutations most frequently 
found in the KRAS and NRAS genes. Patients with meta-
static colorectal cancer harboring RAS mutations do not 
benefit from monoclonal antibodies blocking the EGFR 
[3] and may even have a detrimental effect from treat-
ment with EGFR- inhibitors [4]. Thus, these mutations 
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Abstract
The impact of RAS/RAF mutations in localized colon cancer needs clarification. 
Based on analysis of tumor- specific DNA, this study aimed at elucidating the 
prognostic influence of mutational status in tumor and serum using an extended 
panel of mutations. The study retrospectively included 294 patients with cura-
tively resected stage I–III adenocarcinoma of the colon. Mutations in tumor 
and serum were determined at time of surgery. Analyses were performed with 
droplet digital PCR technology. Hazard ratio (HR) for the association between 
mutational status and survival was estimated in multivariate analysis taking 
known prognostic factors into account. Mutational status in tumor did not on 
its own have significant prognostic impact (P = 0.22). Patients with a RAS 
mutation simultaneously in tumor and serum had a significantly worse prog-
nosis, overall survival (OS) (HR = 2.30, 95% CI = 1.27–4.15, P = 0.0057), and 
disease- free survival (DFS) (HR = 2.18, 95%CI = 1.26–3.77, P = 0.0053). BRAF 
mutation in the serum and proficient mismatch repair (pMMR) protein in 
tumor also indicated significantly worse prognosis, OS (HR = 3.45, 95% 
CI = 1.52–7.85, P = 0.0032) and DFS (HR = 3.61, 95% CI = 1.70–7.67, 
P = 0.0008). In conclusion, RAS mutations in serum, and BRAF mutation in 
serum combined with pMMR in tumor were strong independent prognostic 
factors in patients with RAS/RAF mutated tumors.
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occurring in approximately 50% of colon cancers have 
considerable clinical interest. Mutation analysis performed 
on tissue samples is standard practice before start of 
EGFR- inhibitor treatment. However, while the predictive 
value of RAS mutations as to the benefit of EGFR- inhibitor 
treatment is well established, the overall prognostic impor-
tance of RAS mutations is not clear. Most studies on 
the issue include both colon- and rectal tumors, and a 
possible difference in prognostic value in the two groups 
cannot be extracted from the literature. It is also worth 
noting that almost all studies include only metastatic 
disease or a mixture of metastatic and localized disease, 
likely due to the predictive value of RAS mutations in 
relation to biologically targeted treatment in metastatic 
disease.
The most frequent BRAF mutation is a GTG>GAG 
substitution at position 1799 of exon 15, which results 
in the V600E amino acid change. BRAF mutations occur 
in 8–10% of metastatic colorectal cancers but are reported 
in 10–22% of localized colon tumors. The BRAF muta-
tion holds prognostic information in metastatic disease 
but its potential importance in localized colon cancer 
remains to be proven. Recent studies have not reported 
any significant independent prognostic value of BRAF 
mutations [5–7], but mismatch repair (MMR) status 
may be an effect modifier [8]. A subset of BRAF mutated 
colorectal cancers is characterized by high levels of 
microsatellite instability (MSI- H). The underlying mech-
anism is methylation of the MLH1 promotor, which 
blocks the transcription of mismatch repair protein 
MLH1. Immunohistochemically, these tumors show 
concurrent loss of MSH1 and PMS2. Approximately 
40% of tumors with methylator inactivation of MLH1 
harbor a BRAF mutation. It is possible that MLH1/
PMS2 status modifies the prognostic effect of a BRAF 
mutation.
So far, most studies on the impact of somatic muta-
tions have been based on tumor tissue analyses with 
divergent results. Peripheral blood (plasma and serum) 
may provide a better overall reflection of the status as 
reported in an increasing number of studies [9–11].
Adjuvant chemotherapy benefits only a minor subgroup 
of colon cancer patients and a better selection is of utmost 
importance. New reliable, prognostic markers suitable for 
clinical application may serve an important role for better 
classification of patients for adjuvant chemotherapy or 
close observation.
This study aimed at elucidating the prognostic impor-
tance of RAS/RAF mutations in localized colon cancer 
extending the panel to 27 mutations. Further-
more, the additional prognostic value of mutated DNA 
in serum of patients with a tumor mutation was 
analyzed.
Materials and Methods
Patients
This retrospective study cohort consisted of 294 patients 
who underwent surgery for colon cancer at Vejle Hospital 
between January 1, 2010 and December 31, 2013. The 
inclusion criteria were complete resection (except for 6 
patients (2%) with microscopic involvement of the surgical 
margin), adenocarcinoma, and pTNM stage I- III. Adjuvant 
treatment was given to patients with high- risk stage II 
and stage III (n = 51, 17.4%) according to international 
guidelines [12]. Patients not receiving adjuvant chemo-
therapy and those receiving adjuvant treatment without 
complications (n = 270, 91.8%) were followed with clinical 
examination and a chest and abdominal CT scan one 
and 3 years after the surgery, and then every 5 years 
with colonoscopies until the age of 75. Patients with 
complications during the adjuvant treatment (n = 24, 
8.2%) underwent a follow- up program with chest and 
abdominal CT scan and clinical examination every 
3 months the first year, every 6 months the second and 
third year, and then yearly the fourth and fifth year.
The study was approved by the Ethics Committee for 
Southern Denmark (S- 20140178). The investigation was 
conducted in accordance with the REMARK criteria [13].
Pathology
Tumor tissue was formalin- fixed and paraffin embedded 
(FFPE) by routine methods and all samples were stored 
under standard and consistent conditions. All tumors were 
staged I–III according to UICC and stained by immuno-
histochemistry for MLH1, PMS2, MSH2, and MSH6. Based 
on the staining results, patients were divided into three 
groups: (1) Proficient MMR (pMMR), (2) Loss of MLH1/
PMS2 only (deficient, dMLH1/PMS2 only) and (3) 
Otherwise abnormal MMR expression (dMMR others).
Tumor sample mutation analysis
Droplet Digital polymerase chain reaction (ddPCR) 
(BioRad, Hercules, CA) was used for the analysis of all 
mutations in both tissue and serum as described below.
The investigation included 27 mutations with a frequency 
>0.2% in colorectal cancer. The mutations were selected 
by combining the results from two previous studies [4, 
14]. The analyses were performed in three rounds. We 
tested the three most frequent KRAS mutations (codon 
12: G12D and G12V and codon 13: G13D) and the BRAF 
mutation (V600E) in the first round, and negative samples 
were tested for six mutations occurring less frequently in 
the second round. Leaving out the negative ones, the rest 
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of the panel (17 mutations) was tested in the third round 
(Table S1).
Tumor slides were reviewed for selection of paraffin 
blocks with abundant tumor cells. Three 15 μm slices of 
FFPE tumor tissue were subjected to 180 μL) incubation 
buffer and 20 μL protein kinase K overnight at 70°C. 
Four hundred μl lysis buffer was added to the DNA sam-
ples that were purified on the MAXWELLTM 16 LEV 
instrument using FFPE Plus LEV DNA Purification kit 
(Promega AS1135) according to the manufacturer’s rec-
ommendations. DNA was eluted in 50 μL nuclease- free 
water and further diluted with 500 μL nuclease- free water. 
BioRad ddPCR supermix, PrimePCR ddPCR assays for 
specific mutations (Bio- Rad®, Table S2) and purified DNA 
were mixed with oil and droplets were generated in the 
Automated Droplet Generator (Bio- Rad®). For multiplex 
reactions, wild- type assays and assays for each mutation 
were mixed in equal amounts and 2 μL was used for 
each 20 μL reaction. Forty cycles of PCR amplification 
were carried out (initial denaturation at 95°C for 10 min, 
40 cycles of 94°C for 30 sec and 55°C for 60 sec, and 
final extension at 98°C for 10 min), and the samples 
were analyzed for droplets containing mutated and wild- 
type DNA in the Droplet Reader QX100 (Bio- Rad®). 
Quantasoft ddPCR software ver. 1.7 was used for analyzing 
data. Data were visualized and the concentrations of drop-
lets with a mutation were quantified.
Patients presenting with a RAS/RAF mutation in the 
tumor were selected for serum screening. Based on the 
mutation detected in primary tumor tissue, the blood 
was screened for the specific mutation and analyses were 
performed as described below.
Blood sample mutational analysis
Blood samples were collected at time of surgery (within 
a 4- day window prior to the operation). A 9 mL peripheral 
blood sample was collected and left to coagulate for at 
least 30 min. Serum was isolated by centrifugation at 2000g 
for 10 min within 2 h after collection and stored at −80°C. 
After defrosting the serum was centrifuged at 10,000g for 
10 min. Cysteine- rich polycomb- like protein1 (CPP1) DNA 
fragments were added as exogenous internal control before 
purification [15]. DNA was extracted from 4 mL serum 
with the MagnaPure MPLC Total NA Isolation Kit- Large 
Volume (Roche, Basel, Switzerland) and water was added 
to the samples with inadequate volume prior to purifica-
tion. DNA was eluted in 400 μL. qPCR was performed 
to quantify total cell- free DNA (cfDNA) and CPP1 as 
previously shown [15]. The remaining DNA (380 μL) was 
concentrated to 20 μL on a Millipore centrifugal filter unit 
(Millipore, Billerica, MA). DNA was preamplified 10 cycles 
with Q5 mastermix (New England Biolabs) and PrimePCR 
ddPCR assay (diluted to 0.11 × final concentration) for 
the specific mutation (Bio- Rad®) in 50 μL reaction volumes 
according to the manufacturer’s recommendations. Negative 
controls (water and donor DNA) and positive controls 
were preamplified along with the samples and analyzed 
as the samples. Positive controls for all mutations were 
generated using site- directed mutagenesis as described pre-
viously [16]. DNA was diluted 50–400 times prior to ddPCR 
analysis based on the cfDNA qPCR quantification. 5 μL 
of DNA was combined with PrimePCR ddPCR assays for 
specific mutations (Bio- Rad®) and Bio- Rad® ddPCR super-
mix in reactions of 20 μL for PCR amplification as described 
above. Water and positive controls were included in each 
ddPCR. These were all mixed with oil and droplets were 
generated in an Automated Droplet Generator (Bio- Rad®). 
All samples were analyzed in duplicate. Forty cycles of 
PCR amplification were carried out, and the fluorescence 
signals were analyzed in a Droplet Reader QX100 (Bio- 
Rad®) for droplets positive for FAM or HEX signal cor-
responding to mutated or wild- type DNA. Quantasoft 
ddPCR Software ver. 1.7 was used for analyzing data, data 
were visualized, and the concentrations of droplets with 
mutated or wild- type DNA were quantified.
Data analysis
Limit of blank (LOB) of all mutation detection assays 
was determined on preamplified donor DNA analyzed 
together with the samples. LOB varied among the assays 
from 0 to 0.06% (0–23 copies/well) analyzing a minimum 
of 2 × 30,000 wild- type copies. From merged data of 
double measurement, Quantasoft ddPCR Software calcu-
lated the fraction of mutated alleles/total alleles in patient 
samples. To define a positive sample, the 95% confidence 
interval (95% CI) of the measurements for the donor 
and the sample had to be separate (nonoverlapping). The 
interpretation of the results was identical for RAS and 
BRAF mutations [17].
Results were analyzed using NCSS 10 Statistical Software 
(2015) (NCSS, LLC. Kaysville, Utah, USA, ncss.com/soft-
ware/ncss) and R version 3.2.2 (R Foundation for Statistical 
Computing, Vienna, Austria, 2015). The primary outcome 
measure was overall survival (OS), defined as the time 
from operation to death from any cause. Data on cause 
and date of death were obtained from the Danish Civil 
Registration System. The secondary outcome measure was 
disease- free survival (DFS), defined as the time from opera-
tion to the first documented recurrence, locally or distant, 
of colon cancer or death of any cause. Date of recurrence 
was defined as the date of physician- determined recurrence 
in the clinical notes based on radiography, biopsy, or mul-
tidisciplinary team conference. Patients were censured for 
recurrence at the date of their most recent disease 
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evaluation or hospital contact. The occurrence of secondary 
cancer did not led to censoring of data. Survival analyses 
were carried out using the Kaplan–Meier estimator, and 
survival curves for subgroups were compared using the 
log- rank test. The independent prognostic value of muta-
tion status in tissue and serum was examined by multivariate 
proportional hazard Cox regression, taking known clinical 
risk factors (stage, differentiation, neural- or vascular involve-
ment, and perforation of the peritoneum) into account. 
Validity of the proportional hazard assumption was ensured 
by testing for correlation between Schoenfeld residuals and 
time. To compare the impact of mutation status in tissue 
and serum, respectively, on the prognostic performance of 
the Cox regression models, concordance indices (c- indices) 
were calculated and compared for each of the regression 
models. Additionally, the prognostic influence of variations 
in the quantitative mutation load was examined for patients 
with serum mutations, taking known risk factors into account 
and modeling the mutation load dependence with a restricted 
cubic spline function. All reported P- values were two- sided 
and P < 0.05 were considered statistically significant.
Results
Tumor tissue for mutational analyses was obtained from 
293/294 patients (99.7%) and mutation status in the serum 
was analyzed in 187/189 patients (98.9%) with two samples 
lost because of error in the analyses. Patient characteristics 
are shown in Table 1. pMMR status was found in 73.8% 
of the patients, whereas 21.1% had dMLH1/PMS2 only, 
and 5.1% had other dMMR. A RAS/BRAF tumor muta-
tion was detected in 64.5%, and mutated DNA was found 
in the serum of 42.3% of these patients.
Mutational status
The mutational status is further detailed in Table 2. It 
should be noted that the most frequent KRAS mutations 
in codon 12 and 13 were less frequent in the serum 
compared to the BRAF mutation. Approximately half of 
the tumors with NRAS or BRAF mutation had mutated 
DNA detectable in the serum. A complete list of muta-
tions is given in the supplementary material (Table S3). 
Detection of mutations in the serum varied according to 
stage (Table S4). Seventeen percent (4/24) of patients with 
stage I disease and a mutation in tumor also had a RAS/
BRAF mutation in the serum. The rate increased to 42.9% 
and 51.7% in stage II and III patients, respectively.
Mutation load, expressed as the proportion of mutant 
alleles in cfDNA (mutant and wild- type alleles), was highly 
variable among mutant samples (0.005–11%), median = 
0.098%. Further details are given in the supplementary 
material (Table S4).
Survival analysis
The clinical database was last updated on October 1, 2015. 
Median follow- up time for OS was 3.9 years and for DFS 
3.0 years as estimated by inverse Kaplan–Meier analysis. 
The OS analysis was based on 73 events and the DFS 
analysis on 87 events among 294 patients.
Overall survival according to mutational status in tumor 
and serum is shown in Figure 1A. There was no clinical 
or significant difference in risk of event between patients 
with a wild- type tumor and those with a RAS/BRAF muta-
tion in the tumor (P = 0.22), and the same was true as 
to DFS (P = 0.31). The results remained nonsignificant 
when subdividing patients according to RAS and BRAF 
mutations. There was no significant prognostic influence 
of MMR status when dividing into the three groups 
(pMMR, dMLH1/PMS2 only, and dMMR others).
The analyses demonstrated a significant correlation 
between serum mutations and prognosis. A RAS or BRAF 
mutation both in the serum and in the tumor resulted in 
significantly worse OS (P = 0.012) and DFS (P = 0.026) 
Table 1. Baseline patient characteristics (n = 294).
n (%)
Median age, year (range) 73 (35–94)
Gender
 Female 150 (51)
 Male 144 (49)
pT- category
T1 9 (3)
T2 10 (3)
T3 11 (3)
T4 12 (3)
Stage
I 40 (14)
II 151 (51)
III 103 (35)
Differentiation grade
High 246 (84)
Low 26 (9)
Mucinous 22 (7)
MMR
pMMR 217 (74)
dMLH1/PMS2 only 62 (21)
dMMR others 15 (5)
Tissue
Mutated 189 (65)
Wt 104 (35)
ND 1 (0.3)
Serum
Mutated 80 (42)
Wt 107 (56)
ND 2 (1)
n, number; pT- category, pathologic Tumor stage; MMR, mismatch re-
pair; pMMR, proficient MMR; dMMR, deficient MMR; Wt, wild type; 
ND, not determined.
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compared to a mutation in the tumor only. The effect of 
a RAS mutation alone is shown in Figure 1B, which com-
pares patients with RAS/BRAF wild- type tumors with patients 
harboring a RAS mutation in tissue only and patients with 
a RAS mutation in tissue and serum. The 3- year survival 
rates differed significantly (89% and 61%, P = 0.0012) 
between patients with a mutation in tumor only compared 
to patients with a mutation in both tumor and serum. 
Similar analyses on the effect of a BRAF mutation showed 
a OS of, respectively, 71% and 68% for BRAF mutation 
in tumor alone and in tumor and serum (P = 0.96). The 
combination of BRAF mutated DNA in the serum from 
patients with pMMR tumors, however, indicated a worse 
prognosis (P = 0.0007) as shown in figure 2.
The conventional prognostic factors of OS were analyzed 
in a univariate analysis. Stage I compared to stage III 
disease had the expected effect, HR (stage I/III) 0.50, 
95% CI: 0.25–0.99, although not significant (P = 0.090). 
Neural- or vascular involvement and perforation of the 
peritoneum were highly significant, P = 0.0051 and 
P = 0.0025, respectively. Differentiation grade (high vs. 
low and mucinous combined) was nonsignificant 
(P = 0.47).
To investigate the prognostic value of the mutations 
in the context of conventional prognostic factors, a mul-
tivariate Cox regression analysis included the factors (1) 
RAS mutation detected in both tissue and serum, and 
(2) BRAF mutation in serum combined with pMMR status 
in tumor, in addition to known prognostic factors. BRAF 
mutation in serum and pMMR individually were not tested 
because of the insignificant result in the univariate analysis. 
Adjuvant therapy and number of affected lymph nodes 
were not included in the model because of collinearity 
with the other factors. The results are shown in Table 3.
Harboring detectable RAS mutated DNA in the serum 
remained an independent significant prognostic factor both 
for OS (HR = 2.30, 95% CI = 1.27–4.15, P = 0.0057) 
and DFS (HR = 2.18, 95%CI = 1.26–3.77, P = 0.0053). 
The same applied to BRAF mutation in serum and pMMR 
Table 2. Frequency of mutations in tumor and serum.
Wild type Mutations in tissue (%) Mutations in serum (%)
KRAS Codon 12 + 13 195 98/293 (33.4) 29/98 (29.6)
KRAS Codon 61 + 117 + 146 284 9/293 (3.1) 4/9 (44.4)
NRAS Codon 12 + 13 + 61 287 6/293 (2.0) 3/6 (50.0)
BRAF V600E 217 76/293 (25.9) 44/76 (57.9)
ND — 1 3
ND, not determined.
Figure 1. Overall survival. (A) OS according to mutational status. Three- 
year survival rates were 81%, 84%, and 65%, respectively. (B) OS 
according to RAS mutational status. Three- year survival rates where 
81%, 89%, and 61%, respectively.
(A)
(B)
Figure 2. Overall survival for BRAF mutation in serum and pMMR in 
tumor. OS according to BRAF mutational status in the serum and MMR 
status in the tumor. Three- year OS rates were 79% and 42%, 
respectively.
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in tumor. These characteristics were independently related 
to worse OS (HR = 3.45, 95% CI = 1.52–7.85, P = 0.0032) 
as well as DFS (HR = 3.61, 95%CI = 1.70–7.67, P = 0.0008). 
Perforation of the peritoneum also remained significant 
in the multivariate analysis. A comparable model based 
on tissue mutations and MMR status (including the same 
standard prognostic factors) did not show any impact of 
mutation status on OS and DFS. The c- index for the 
Cox model taking serum mutation status into account 
was 0.67 (95% CI = 0.60–0.74), which was significantly 
better than the c- index for the model using tissue muta-
tion status (P = 0.01).
All factors except for neural- or vascular involvement 
met the proportional hazard assumption as did the model 
in general. A robustness analysis including neural- or 
vascular involvement as a stratification factor rather than 
as a model parameter resulted in almost identical hazard 
ratios and P- values for the impact of mutational status.
As an illustration of the prognostic value of RAS muta-
tion in the serum, we estimated the 3- year OS of a standard 
patient (stage II disease, highly differentiated tumor, no 
perforation of peritoneum, no neural- or vascular involve-
ment, and no BRAF mutation) based on the multivariate 
Cox regression analysis. The estimated 3- year OS for such 
a patient without a RAS mutation in the serum was 86% 
(95% CI = 80–92%) and with a RAS mutation 70% (95% 
CI = 57–87%). This is different from the model based 
on RAS mutational status in tissue: 84% (95% 
CI = 78–92%) without RAS mutation and 83% (95% 
CI = 76–91%) with RAS mutation. See supplementary 
material for graphical illustration of the estimated survival 
curves with/without RAS mutations, taking other prog-
nostic factors into account (Figs. S1- S4).
The mutational load also held prognostic information. 
Figure 3 illustrates the 3- year survival rate based on Cox 
regression analysis with conventional prognostic factors 
and mutation load as continuous variables. The effect on 
survival appears most marked in the interval 0.1–1.0% 
mutated alleles.
Discussion
Colon cancer represents a major therapeutic challenge. 
Surgery is a cornerstone in the standard treatment strategy, 
but is not always curative, especially in patients with stage 
III disease. Additionally, adjuvant chemotherapy has short-
comings. It provides a minor improvement in overall 
survival but may have serious side effects. These challenges 
call for proper selection of patients, and the generally 
accepted criteria [12] are inadequate. Consequently, new 
prognostic markers have high priority, especially in patients 
with stage II disease.
Mutations are important to the biology of colon cancer 
and the RAS and RAF mutations in tumor tissue have 
been extensively investigated as predictive and prognostic 
markers, particularly in the metastatic setting. Routine 
assessment of the RAS mutational status is performed 
to personalize treatment of metastatic disease, and the 
panel of mutations analyzed has expanded through the 
years.
At present, there is no consensus on the prognostic 
impact of RAS/RAF mutations in localized disease, but 
it is noteworthy that almost all studies are based on 
analyses of KRAS codon 12 and 13 together with BRAF 
V600E (a total of eight mutations). This study aimed at 
investigating whether the contradictory results in the lit-
erature could be explained by a too narrow panel of 
mutations. The results, however, did not suggest any 
prognostic importance of an expansion toward a broader 
panel of analyzed mutations. Our results are in agreement 
with a study by Roth et al. [18] who analyzed 1404 stage 
Table 3. Cox regression analysis.
OS HR (95% CI) DFS HR (95% CI)
RAS mutation in serum 2.30 (1.27–4.15) 2.18 (1.26–3.77)
BRAF mutation in serum 
and pMMR in tumor
3.45 (1.52–7.85) 3.61 (1.70–7.67)
Stage
I vs. II 1.13 (0.50–2.59) 1.16 (0.54–2.50)
I vs. III 1.33 (0.56–3.16) 1.28 (0.57–2.89)
Differentiation
High vs. low 0.99 (0.43–2.31) 0.91 (0.42–1.99)
High vs. mucinous 1.41 (0.59–3.38) 1.17 (0.50–2.72)
Neural- or vascular 
involvement
1.48 (0.84–2.59) 1.58 (0.94–2.66)
Perforation of the 
peritoneum
2.10 (1.09–4.04) 1.87 (1.02–3.45)
The analysis is based on all patients with full data (n = 291).
Figure 3. Overall survival for quantitative mutation load. An illustration 
of the dependence of 3- year OS on the quantitative measurement of 
the mutation load. NOTE: Because of the broad range of values, the 
x- axis is logarithmic.
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I–III colon cancer patients and found a frequency of KRAS 
mutations similar to our results but no prognostic impact 
on OS (P = 0.45). On the other hand, a study with 1989 
patients concluded that KRAS mutation was associated 
with worse survival [19]. This investigation, however, dif-
fers from ours in several aspects. It included both rectal-
 (33%) and colon cancer and metastatic disease (11%). 
It should also be noted that a stratified analysis by stage 
showed no significant influence of KRAS mutations on 
the OS in localized disease (HR = 1.19, 95%CI = 0.87–1.63) 
and 29% of the patients had missing information on KRAS 
status.
BRAF mutations are anticipated to have prognostic 
impact in metastatic colorectal cancer [20, 21], but their 
importance in localized disease is dubious. A study with 
364 stage II and III colon cancer patients reported a poor 
prognosis for patients with BRAF mutations in tumor 
independent of age, stage, grade, differentiation, MMR 
status, and location [22]. It is notable that 71% of the 
patients received adjuvant chemotherapy, which is a large 
fraction of an average population with stage II–III disease, 
hampering comparison with our study where 17% received 
adjuvant chemotherapy. Previous reported results [23, 24] 
and a recent review point to a prognostic impact of BRAF 
mutations together with MMR status and location [8]. 
Our results confirmed this finding. The proportion of 
sporadic dMMR cancers (group B) is similar to what is 
found in the background population. MMR status was 
divided into three groups to separate sporadic cancer and 
dMMR from patients with possible Lynch Syndrome.
Analysis of serum mutations calls for high sensitivity, 
especially in localized disease with low tumor load. ddPCR 
has a sensitivity of around 10−4 as also found in our 
study. An important factor is the LOB, which sets the 
lower level of mutation detection in the current sample 
[25]. We classified a sample as positive if the value was 
above the upper level of the 95%CI of the negative control 
samples. Plasma is probably preferable to serum for muta-
tion analysis because of contaminating wild- type DNA in 
serum [26]. We used serum, since plasma was not avail-
able and the low LOB allowed for a high sensitivity, but 
mutations occurring at very low frequencies cannot be 
excluded. On the other hand, mutations at very low fre-
quencies (<0.1%) only seem to have marginal prognostic 
influence (Fig. 3).
The presence of a RAS mutation in the serum had 
a significant prognostic value, both in the univariate 
and multivariate analysis. The literature on this issue 
is sparse and the results are difficult to interpret because 
of different methodologies and patient materials. The 
majority of the studies included both colon- and rectal 
cancer, and it is well known that the frequency of RAS/
RAF mutation differs with the location of the tumor. 
Additionally, most studies included localized as well as 
metastatic disease and were based on small numbers of 
patients as described in a recent review [27]. The first 
prospective study from 2003 found no prognostic impact 
on disease recurrence of KRAS mutation in the serum 
preoperatively. Despite a high relative hazard of 2.07 
the difference was not significant (95%CI = 0.3–14.8, 
P = 0.466) [9]. The study did not report on OS. The 
authors found a much higher frequency of KRAS muta-
tions (codon 12 and 13) in the serum, provided that 
the tumor was KRAS mutated, 76% as opposed to 30% 
in this study. The trial differs from our study in many 
important aspects. It was a smaller study than ours 
(n = 32/78 with a KRAS mutation in the serum) and 
they had a more inhomogeneous cohort including rectal 
cancer (50%) and metastatic disease (14%). Follow- up 
was only reported for 49 patients (63%) and median 
follow- up was not stated. Furthermore, they analyzed 
for the seven most frequent KRAS mutations (codon 
12 and 13).
We found that the frequency of BRAF mutations in 
the blood was almost doubled compared to that of 
RAS (58% vs. 32%). BRAF mutation in the serum alone 
was not significant as a prognostic factor. In agreement 
with the theory that MMR status links prognosis with 
BRAF mutational status, we found a statistically sig-
nificant negative prognostic value of BRAF mutation 
in the serum from patients with pMMR in tumor. The 
independent prognostic influence was confirmed in the 
Cox regression analysis. To our knowledge our data 
are the first to indicate a prognostic relation between 
BRAF mutation status in the blood and MMR status 
in the tumor.
In the multivariate analysis we tested the prognostic 
value of RAS mutation in the serum and the combination 
of BRAF mutation in the serum and pMMR in the tumor 
against conventional prognostic factors and they both 
remained statistically significant. They came out stronger 
than the indicators used conventionally. The independent 
value was shown in the Cox regression analysis but should 
be considered with caution because of the wide confidence 
limits. The c- index indicated that the prognostic model 
using serum status performed significantly better than a 
model using tissue mutation status.
This study provides new information on different aspects 
of RAS/BRAF mutations. The results failed to show any 
impact of mutations in tumor tissue even using an expanded 
panel of mutations screened for, which to the best of 
our knowledge has not been reported previously. The 
analysis of tumor- specific DNA in serum holds new, origi-
nal information. The same applies to the correlation 
between OS and the quantitative load of mutations. The 
study opens for the potential use of analysis of RAS 
935© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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mutations in serum in the clinical management of colon 
cancer, together with a combination of BRAF mutations 
in serum and tumor MMR status. Neoadjuvant chemo-
therapy may be an option in the near future and plasma 
mutations may serve as a tool for relevant selection. Further 
prognostic subclassification seems to be possible by quan-
tification of the mutational load as recently suggested [28]. 
A similar result was found in this study.
There are, however, limitations of the study. First of 
all, its retrospective nature calls for prospective validation. 
Therefore, our study can only be considered hypothesis 
generating. The study only investigated RAS/RAF muta-
tions, and other mutations with prognostic value were 
disregarded but this fact does not diminish our main 
finding of the prognostic influence of serum mutations 
in RAS/RAF mutated tumors. Additionally, the subgroup 
of patients with BRAF mutation in serum and pMMR 
in tumor was small (n = 14). A number of additional 
prognostic factors could have been considered for the 
multivariate analysis. It is generally accepted that tumor 
location has a role in the prognostic impact of BRAF 
mutations. According to the literature the subgroup of 
left- sided tumors with pMMR, and BRAF mutation in 
the tissue have the worst prognosis [8]. However, location 
was not included in our analysis because this subgroup 
was very small (n = 3) and pMMR, left- sided tumors 
and BRAF mutation in the serum even smaller (n = 1). 
It could be argued that CEA in the blood should be 
considered as well but CEA is not a validated prognostic 
marker according to the ESMO guidelines [12]. A further 
limitation is the different follow- up according to the course 
of adjuvant treatment, which will influence the estimate 
for disease- free survival, although this subgroup was small 
(8%).
In conclusion, this study demonstrates a considerable 
clinical importance of mutations in the serum and under-
lines the value of “liquid biopsy”. These results emphasize 
the perspectives of applicating this method in the daily 
clinical routine but should be further developed and vali-
dated in prospective studies.
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